Results: Both olanzapine (100 uM) and clozapine (100 uM) significantly increased pERK1/2 and pJNK protein expression, while aripiprazole (20 uM) only increased pJNK. Clozapine (100 uM) and aripiprazole (5 and 20 uM) significantly increased AMPK phosphorylation and inhibited insulin-induced phosphorylation of AKT. Olanzapine (100 uM) treatment caused a significant increase in IL-6 while aripiprazole (20 uM) significantly decreased IL-10. Olanzapine (100 uM) and aripiprazole (20 uM) increased BDNF expression. Discussion: All the APs studied upregulated pJNK, along with olanzapineassociated increases in IL-6, and aripiprazole-associated decreases in IL-10, together suggesting AP-mediated upregulation of pro-inflammatory pathways in rHypoE-19 neurons. Aripiprazole and clozapine (but not olanzapine) inhibited insulin-stimulated AKT, suggesting impaired hypothalamic insulin action by some, but not all, APs. Clozapine additionally increased AMPK phosphorylation (activation), an orexigenic energy sensor, which would also be expected to disrupt energy homeostasis. Conversely, olanzapine and aripiprazole increased BDNF, a factor linked to the underlying etiology of schizophrenia, suggesting BDNF upregulation may be a mechanism of therapeutic action. Taken together, our findings suggest differential and pleotropic effects of APs on neuroinflammation and energy sensing in the hypothalamus, which do not necessarily align consistently with known metabolic liability of these agents (i.e. clozapine = olanzapine > aripiprazole). Our data warrants further exploration into the mechanism of these effects, including replication of these effects in an in vivo model.
F236. CLONIDINE NORMALIZES MMN IN SCHIZOPHRENIA PATIENTS ON STABLE MEDICATION

Center for Neuropsychiatric Schizophrenia Research (CNSR) Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Copenhagen University Hospital, Psychiatric Center Glostrup
Background: Schizophrenia is a severe brain disorder with profound deficits in prefrontal cortical cognitive functioning. These cognitive deficits form a core feature in schizophrenia for which treatment has been proven to be clinically challenging. One of the key neurotransmitters involved in cognitive functioning is noradrenaline. Previous research has demonstrated disrupted noradrenergic activity in schizophrenia while several studies report improvements in prefrontal cognitive functioning by a selective α2-agonist. Clonidine is such a selective α2A-agonist and previous research in our lab has demonstrated that a (range of) single dosage(s) of clonidine normalize(s) sensory gating in chronically ill, yet stably medicated patients with schizophrenia. Currently, we investigated if clonidine also normalizes Mismatch Negativity (MMN) deficits in this same group of patients. This is important, since reports have shown that MMN amplitude is associated with negative symptoms and cognitive functioning in schizophrenia. Methods: In a pseudo-randomized, double-blind, placebo-controlled experiment twenty chronically ill, yet stably medicated, male patients with schizophrenia were tested with the MMN paradigm from the Copenhagen Psychophysiological Test-Battery (CPTB) on 5 different occasions, each separated by a week. Four hours prior to testing patients were randomized administered either a placebo (non psycho-active compound) or a single dose of 25, 50, 75 or 150 μg of clonidine (Catapresan) on top of their usual medication on each occasion, in such a way that each patient received every dose once. Patients were matched on age and gender with 20 healthy controls (HC), who did not receive any treatment. The MMN paradigm consisted of 1800 stimuli with 4 types of stimuli: 1 standard (1000 Hz, 50 ms) presented 82% of the time and 3 types of deviants, based on either frequency (FreqMMN: 1200 Hz, 50 ms), duration (DurMMN: 1000 Hz, 100 ms) or their combination (FreqDurMMN: 1200 Hz, 100 ms) each with a probability of 6%. All stimuli had an intensity of 75dB and were presented with an interstimulus interval randomized between 300 and 500 ms. Subjects were requested to ignore all stimuli and were therefore watching a (muted) nature documentary. Results: In the placebo condition, patients had significantly reduced DurMMN and FreqDurMMN amplitude compared to HC, whereas FreqMMN did not show significant group differences. Furthermore, all doses of clonidine normalized FreqDurMMN amplitude in such a way that it was not significantly different anymore from the HC, while DurMMN only normalized with the highest dose (150ug). Discussion: Our results indicate disrupted MMN amplitude in chronically ill patients with schizophrenia in spite of the fact that they were stable on their medical treatment. In addition, our data provide evidence that a single dose of clonidine is able to normalize MMN amplitude in these patients. Furthermore, patients could not distinguish between the placebo and the treatment conditions or reported any side effects of these low doses of clonidine. Together with our previous reports indicating normalized sensory and sensorimotor gating in these patients following administration of clonidine, our results could be of potential high clinical relevance in the treatment of schizophrenia. Future studies should therefore focus on longer trial periods to investigate if clonidine, besides normalizing MMN amplitude and sensory(motor) gating, can also ameliorate negative symptoms and cognitive functioning in schizophrenia. 
F237. DOPAMINERGIC EFFECTS ON HIERARCHICAL PREDICTION ERRORS AND CONNECTIVITY DURING SOCIAL LEARNING
Max Planck Institute for Metabolism Research
Background: Persecutory delusions (PD) constitute core symptoms in psychosis that may emerge from aberrant learning and inference about others' intentions. Computational assays that use generative models of electrophysiological data to probe this learning process and its underlying neuronal mechanisms, in particular the effects of dopamine (DA) on synaptic plasticity, could provide mechanistic insights into the emergence of PD in psychosis. More importantly, they could enable prediction of individual treatment response to DA antagonists and thus help to address an important problem of clinical management of psychosis. Methods: We tested 137 healthy volunteers (mean age: 22 ± 3) in a double-blind, placebo-controlled, between subject pharmacological study: placebo (n = 47), DA precursor L-Dopa (n = 45), and DA receptor antagonist amisulpride (n = 45). Electroencephalography was recorded using a 128-channel Brain-Vision system. Participants performed a social learning task that required learning about an adviser's intentions and how they changed over time. Subsequently, we modeled participants' behavior with the hierarchical Gaussian filter (HGF), a model in which learning is driven by hierarchical prediction error (PE) updates: At the first level, positive PEs indicate that advice was better than expected (advice PE: aPE). At the second level, a positive PE signals that the adviser's intentions were less stable than predicted (volatility PE: vPE) . Using the trial-wise estimates from the HGF, we performed single-trial EEG analyses of PE activity at sensor and source levels. We also examined DA effects on effective connectivity with dynamical causal modelling (DCM). To this end, we divided event-related potentials (ERPs) according to PE magnitudes into 2 bins corresponding to positive and negative PEs.
Results: At the sensor-level, we identified distinct temporal profiles of hierarchical PEs (peak effects: aPE at 112ms, vPE at 276ms). In source space, three sources showed significant effects for both PEs: anterior temporoparietal junction (TPJ), dorsal middle cingulate cortex (MCC) and supplementary motor cortex (SMA).
To identify the connections that convey PEs, we compared two DCM families that allowed input to different nodes of the network, and different modulatory effects of PE magnitude. The family with input entering the SMA and propagating via MCC to TPJ explained aPE-evoked activity best, whereas the family with input into the TPJ and propagating in the opposite direction best described the effects of vPE-evoked activity. Bayesian model selection identified the winning model for aPE effects; this model proposed PE magnitude modulations of input gain and effective connectivity from TPJ to MCC, and MCC to SMA. Conversely, a model with connectivity modulation from MCC to TPJ best described the effects of vPE. Second, we investigated the impact of dopaminergic perturbations of the network by comparing DCM parameters of the winning models across pharmacological groups. Post hoc t-tests revealed that DA impacted on aPE-induced perturbations only, which is in line with previous findings that aPEs are represented in dopaminergic regions while vPEs are likely encoded by activity in cholinergic regions. Specifically, DA modulated TPJ-MCC and SMA-MCC connectivity. Discussion: Model-based analysis of EEG data in a social learning task detects DA effects on connectivity, even when behavior (accuracy, reaction time) was not affected by the drugs. Currently, we are extending our computational approach to first-episode schizophrenia patients, where we hope to use parameters from neuronal and behavioral models to predict individual treatment response. Background: Social functioning deficits are of critical importance in patients with schizophrenia, because they affect the long-term outcomes and quality of life (QOL) of the patients. Two aspects of social functioning, namely, competence (ability to perform skilled activities, that is, what one can do) and performance (actual performance of skilled activities, that is, what one actually does) are considered to have a significant influence on how well the patients can live independently in the community. Although the two aspects are usually thought to go hand in hand, discrepancy between the two is often observed in patients with schizophrenia in clinical practice. Some patients are not able to function in the community to the best of their ability; some patients appear to get along everyday living better than they would be expected to. The aim of the present study was to identify factors influencing the occurrence of such discrepancy of social functioning in patients with schizophrenia. Methods: A total of 205 stable outpatients with schizophrenia aged 40 years old or under were recruited at the Toho University Omori Medical Center, Tokyo. Of the 205 patients, 100 were male (48.8%) and 105 (51.2%) were female. The mean age of the participants was 29.3 years and the mean estimated premorbid IQ was 100.8. The mean age at disease onset was 22.0 years old, and the mean duration of illness at the start of the study was 6.7 years. The social functioning, psychiatric symptoms, social anxiety, cognitive function, and QOL of the participants were assessed. The patients were divided into 4 groups by the cutoff points for competence and performance calculated using a comprehensive dataset of the Social Functioning Scale (SFS) obtained from multiple facilities. Results: The subjects were divided according to their level of competence and performance as follows: good competence and good performance (CP) group, 108 (52.7%) patients; good competence but poor performance (Cp) group, 40 (19.5%) patients; poor competence but good performance (cP) group, 13 (6.3%) patients; poor competence and poor performance (cp) group, 44 (21.5%) patients. Among the 4 groups, the objects of particular interest in this study were the differences between CP and Cp groups and between the cP and cp groups. One-way ANOVA revealed significant differences among the groups in the scores on the Positive and Negative Syndrome Scale (PANSS), Liebowitz Social Anxiety Scale (LSAS), Global Assessment of Functioning Scale (GAF), World Health OrganizationQuality of Life 26 (WHOQOL26), and Social Functioning Scale (SFS). Post-hoc comparisons revealed that the PANSS negative symptoms and general psychopathology scores, GAF score, WHOQOL26 score, and SFS total score were significantly worse in the Cp group than in the CP group, and that the LSAS score, GAF score, WHOQOL26 score, and SFS total score were significantly better in the cP group than in the cp group. Discussion: In patients who are capable of living well in the community but do not perform well, negative symptoms may be involved in this discrepancy of social functioning. Patients who are able to maintain themselves well despite their poor social competence appear to have milder social anxiety symptoms as compared to patients who are neither competent nor capable of performing well in terms of social functioning in the community. Suitable and personalized approaches based on the patients' profile of dysfunction would seem to be indispensable for the recovery of such patients. Background: Optimizing psychosocial functioning and overall well-being by reducing the severity of negative symptoms are important outcomes for individuals with schizophrenia. Movement-based therapeutic approaches are uniquely capable of addressing the non-verbal nature of negative symptoms. Dance/Movement Therapy (DMT), a promising treatment for mental health conditions such as schizophrenia, has been found to reduce the occurrence and severity of negative symptoms and to have a positive impact on the psychosocial functioning. Although preliminary findings suggest DMT as a treatment intervention, limited research and inconclusive findings preclude generalizations and more research is needed. We aimed to examine the treatment effects of a 10-week (20 sessions) group DMT treatment program. Methods: We employed a mixed methods intervention design with explanatory intent, in which a randomized controlled trial is followed by semistructured exit interviews. Thirty-one severely ill individuals diagnosed with schizophrenia participated in the RCT that used a two-arm parallel group design to assess and show the difference between patients receiving standard care (SC) and patients receiving standard care plus DMT on measures of negative symptoms (as primary outcome; PANSS, BNSS) and psychosocial functioning (as secondary outcomes; WHO-DAS 2.0, SDS). Quantitative measures were taken pre and post-intervention. Participants who participated in a minimum of 50% of DMT sessions (n=15) were invited to an exit interview. This criterion was also used to analyze quantitative data, leaving n=28 for quantitative analysis.
F238. COMPETENCE-PERFORMANCE
F239. THE ROLE OF DANCE/MOVEMENT
